STOCK TITAN

Cymabay Therapeutics Inc - CBAY STOCK NEWS

Welcome to our dedicated news page for Cymabay Therapeutics (Ticker: CBAY), a resource for investors and traders seeking the latest updates and insights on Cymabay Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cymabay Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cymabay Therapeutics's position in the market.

Rhea-AI Summary
CymaBay Therapeutics, Inc. granted 99,000 stock options to three employees on February 16, 2024, with an exercise price of $32.18 per share. The options will vest over time based on continued employment, aiming to incentivize and retain key talent.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
CymaBay Therapeutics, Inc. (CBAY) announced that the FDA accepted its NDA for seladelpar, a treatment for PBC, with a target PDUFA date of August 14. Seladelpar has shown significant improvements in PBC-related markers and pruritus in Phase 3 studies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25.38%
Tags
clinical trial
-
Rhea-AI Summary
Gilead Sciences acquires CymaBay Therapeutics for $4.3 billion to add seladelpar, a PPARδ agonist for the treatment of Primary Biliary Cholangitis (PBC), with FDA priority review and anticipated US approval in the third quarter of 2024. Seladelpar Phase 3 data showcases a best-in-disease profile for second-line PBC, expanding Gilead's liver disease portfolio and commitment to patient care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25.38%
Tags
acquisition
Rhea-AI Summary
Gilead Sciences acquires CymaBay Therapeutics for $4.3 billion to add seladelpar, a PPARδ agonist for the treatment of Primary Biliary Cholangitis (PBC), with FDA priority review and anticipated US approval in the third quarter of 2024. Seladelpar Phase 3 data showcases a best-in-disease profile for second-line PBC, expanding Gilead's liver disease portfolio and commitment to patient care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.06%
Tags
acquisition
-
Rhea-AI Summary
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) announced its management team's participation in upcoming healthcare conferences, including the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference, Raymond James & Associates’ 45th Annual Institutional Investors Conference, and Leerink Partners Global Biopharma Conference. The conferences aim to showcase the company's innovative therapies for liver and chronic diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.59%
Tags
conferences
-
Rhea-AI Summary
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) granted inducement awards to two employees on January 12, 2024. The Compensation Committee approved the grant of non-qualified stock options to purchase 52,000 shares of CymaBay common stock. The stock options have an exercise price of $23.76 per share and will vest over time based on the employees' continued employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.91%
Tags
none
Rhea-AI Summary
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) announced the first published findings demonstrating the impact of seladelpar on serum interleukin-31 (IL-31) levels and its correlation with pruritus improvement in people with primary biliary cholangitis (PBC). The Phase 3 ENHANCE study showed statistically significant dose-dependent decreases in IL-31 with seladelpar compared to placebo. The findings were published in the open access journal Hepatology, marking a significant step in understanding the potential mediators of cholestatic itch and suggesting novel therapeutic approaches for PBC patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.08%
Tags
clinical trial
-
Rhea-AI Summary
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) announces President and CEO Sujal Shah's presentation at the 42nd Annual JP Morgan Healthcare Conference on January 10, 2024, focusing on innovative therapies for liver and chronic diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.38%
Tags
conferences
-
Rhea-AI Summary
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) granted inducement awards to four employees on December 15, 2023. The Compensation Committee approved the grant of non-qualified stock options to purchase 176,000 shares of CymaBay common stock. The stock options have an exercise price of $22.03 per share and will vest over time based on the employees' continued employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) submits NDA for seladelpar, a potential treatment for primary biliary cholangitis. The NDA is supported by data from over 500 patients, with Phase 3 trial results demonstrating significant improvement in markers of cholestasis and PBC-related pruritus. Seladelpar has been granted Breakthrough Therapy Designation by the FDA and is the only potent, selective, orally active delpar with promising results in clinical trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.8%
Tags
none
Cymabay Therapeutics Inc

Nasdaq:CBAY

CBAY Rankings

CBAY Stock Data

3.70B
95.02M
0.4%
104.53%
8.2%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Newark

About CBAY

cymabay therapeutics is a clinical-stage biopharmaceutical company located in the san francisco bay area focused on developing therapies to treat metabolic diseases with high unmet medical need or serious rare and orphan diseases. we are committed to developing breakthrough medicines that improve the lives of patients and their families. cymabay was seeded with the assets from an earlier metabolic disease company in which more than $120m was invested to produce a robust pipeline.